Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H1 2020

Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H1 2020



According to the recently published report Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H1 2020; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H1 2020 outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
Assuage Pharmaceuticals Inc
H. Lundbeck AS
Jeil Pharmaceutical Co Ltd
Kyung Dong Co Ltd
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisinicline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JLP-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Assuage Pharmaceuticals Inc, H1 2020
Pipeline by H. Lundbeck AS, H1 2020
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
Pipeline by Kyung Dong Co Ltd, H1 2020
Pipeline by Sopharma AD, H1 2020
Pipeline by Suven Life Sciences Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drugs In Development, 2021

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drugs In Development, 2021Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the

USD 3500 View Report

Neuronal Acetylcholine Receptor Subunit Beta 4 (CHRNB4) - Drugs in Development, 2021

Neuronal Acetylcholine Receptor Subunit Beta 4 (CHRNB4) - Drugs in Development, 2021Neuronal Acetylcholine Receptor Subunit Beta 4 (CHRNB4) - Drugs in Development, 2021 provides in depth analysis on Neuronal Acetylcholine

USD 3000 View Report

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drugs In Development, 2021

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drugs In Development, 2021Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by

USD 3500 View Report

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drugs In Development, 2021

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drugs In Development, 2021Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 10 molecules. The latest report Muscarinic Acetylcholine Receptor M2 - Drugs

USD 3500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available